Global Validation Regulations & Standards
Cleaning Validation for Highly Potent and HPAPI Products: US vs EU Views Validation is a critical element in the pharmaceutical industry, particularly when addressing cleaning processes for Highly Potent Active Pharmaceutical Ingredients (HPAPIs). As the regulatory landscape continues to evolve, it is vital for professionals in the pharma and regulatory sectors to understand the distinct perspectives and requirements from key…
Biologics Validation: Differences in US, EU and UK Regulatory Expectations The validation of biologics is a critical process that ensures the safety and efficacy of products in compliance with global regulatory standards. This article delves into the distinct expectations of biologics validation as outlined by the US FDA, EMA, MHRA, and PIC/S. We will explore various aspects such as definitions,…
Validation Sampling Plans: Differences in Statistical Expectations Among Agencies Validation Sampling Plans: Differences in Statistical Expectations Among Agencies In the realm of pharmaceutical validation, understanding the sampling expectations set forth by regulatory authorities such as the US FDA, EMA, and MHRA is crucial for compliance and quality assurance. Each agency articulates its guidelines through specific frameworks that affect how validation…
CAPA Expectations in Validation-Related Deficiencies: FDA vs EMA vs MHRA CAPA Expectations in Validation-Related Deficiencies: FDA vs EMA vs MHRA Understanding Validation CAPA Expectations Corrective and Preventive Action (CAPA) is a critical component of the Quality Management System (QMS) as it pertains to validation within pharmaceutical manufacturing and development. Regulatory agencies such as the FDA, EMA, and MHRA place a…
Hybrid Facilities Serving US, EU and UK: Designing Validation Programs for All Regions In the dynamic landscape of pharmaceutical manufacturing, global operations are becoming increasingly prevalent as companies seek to market multi-market products across diverse regulatory environments. As a result, regulatory expectations for validation activities in facilities serving multiple regions—specifically those operating under the jurisdictions of the US FDA, EMA,…
GDP and Cold Chain Validation: US vs EU Expectations Cold chain management and Good Distribution Practice (GDP) validation are critical components in ensuring that pharmaceuticals are transported and stored under appropriate conditions throughout the supply chain. In regions like the US, UK, and EU, regulatory bodies such as the FDA, EMA, and MHRA enforce stringent standards to mitigate risks associated…
Medical Device and Combination Product Validation: FDA vs EU MDR/IVDR In the rapidly evolving landscape of pharmaceuticals and medical devices, validation has emerged as a cornerstone of ensuring product quality, safety, and efficacy. With the implementation of distinct regulatory frameworks across regions, notably the United States and Europe, understanding the nuances of validation requirements is essential for pharma and regulatory…
ICH Q12 Implementation: Impact on Validation and Post-Approval Changes by Region Understanding ICH Q12 and Its Relevance to Validation The International Council for Harmonisation (ICH) has established guidelines aimed at ensuring the quality, safety, and efficacy of pharmaceuticals. ICH Q12, titled “Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management,” is the most recent addition to this set of standards….
Validation Inspection Trends: Comparing FDA 483s, EMA and MHRA Deficiency Data Introduction to Validation Inspection Trends In the pharmaceutical industry, the integrity, safety, and efficacy of products are paramount. The validation process ensures that manufacturing processes, cleaning protocols, and equipment function as intended. Regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and…
Contract Manufacturer Oversight: Sponsor Expectations Under US, EU and UK Regulations Contract Manufacturer Oversight: Sponsor Expectations Under US, EU and UK Regulations In the pharmaceutical industry, contractmanufacturing organizations (CMOs) are integral to the production and supply of medicinal products. Ensuring that these external partners operate in compliance with regulatory requirements is a significant concern for sponsors. This guide aims to…